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noted during the captopriVthiazide treatment period (X2 df
I = 7,2; P < 0,01). CaptopriVthiazide-associated side-effecrs
were noted by 18 men; these included excess sweating (8
men), tiredness (4), abdominal discomfort (2), impotence (2)
and coughing (2). Six men noted side-effects during the
methyldopalprazosin treatment period; drowsiness (5) and
impotence (3).
The majority of patients (37) were satisfied with both
regimens. One patient liked neither regimen. Fifteen men did
not like the captopril regimen and 4 did not like the methyl-
dopalprazosin regimen (X 2 df I = 7,1; P < 0,01). Thirty-three
of the 37 men who found both regimens acceptable, preferred
the captopril regimen.
Discussion
The two regimens studied may not be strictly comparable
although each would be considered to be suitable for the
management of moderate hypertension. In black subjects with
hypertension, renin levels are usually 10w4 and ACE inhibitors
alone have been shown to be relatively ineffective.5 However,
with the addition of a thiazide diuretic, ACE inhibitors have
been used successfully for the control of hypertension in black
South Mricans.5 The present study has shown that the ACE
inhibitor/thiazide diuretic regimen was less effective than the
methyldopalprazosin regimen in controlling the blood pressure
in black men with moderate hypertension.
The men who found both regimens acceptable expressed a
preference for captopril, which lends support for the view that
patients on captopril feel beter than do those on other anti-
hypertensive regimens.' On the other hand, the captopril
regimen was tolerated by significantly fewer men than was the
methyldopalprazosin regimen.
The methyldopalprazosin regimen is less expensive and, in
this study, was more acceptable and more effective than the
captopril regimen.
I wish to thank Mr Emest Mbeka for organising the special
clinics for the study and Mr Simon TIadi who did all the blood
pressure measurements. Professor F. J. Milne kindly reviewed the
manuscript.
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The long-term efficacy and safety of sustained-release dil-
tiazem (Tilazem; Parke-Davis) were evaluated. A total of 27
young, physically active patients with hypertension were
followed up for 17 months. On a dosage of 90 mg twice daily,
adequate blood pressure reduction was obtained in 23
patients (85%). No adverse effects were noted.
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In a previously published double-blind parallel study the
short-term antihypertensive efficacy of sustained-release (SR)
Department of Cardiology, Institute for Aviation Medicine,
Verwoerdburg, Tvl
D. P. MYBURGH, MB. CH.B., DIP.A.C.P., F.A.C.C.
Accepted 30 Mar 1990.
Reprint requests [0: Dr D. P. Myburgh, Dept of Cardiology, Institute for Aviation Medicine,
Private Bag lG, Verwoerdbwg, 0140 RSA.
diltiazem (Tilazem; Parke-Davis) was compared with that of
atenolol.' The study was extended in order to evaluate the
long-term efficacy and safety of the SR formulation of dil-
tiazem.
Patients and methods
The study comprised 27 patients and the fIrst phase - the
comparison of the antihypertensive efficacy of SR diltiazem
with that of atenolol' - lasted 5 months. On termination of
this phase, 14 patients controlled on SR diltiazem were followed
up for another 12 months. The 13 patients on atenolol were
switched to SR diltiazem 90 mg twice daily and followed up
for another 17 months. :.
The patients were all men and were specifically selected on'
the basis of youth (mean age 32 ± 2 years) and being physically
active. 1
Patients were evaluated at monthly intervals in the morning
12 - 14 hours after their last dose of SR diltiazem. Blood
pressure was measured by conventioI].al mercury sphygmo-
manometry in triplicate at rest, after 5 minutes in the supine
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position, and after 2 minutes of standing. Systolic and diastolic
blood pressures were determined by phase I and V Korotkoff
sounds, respectively. A resting ECG, chest radiography, body
mass determination and laboratory investigations were per-
formed before treatment and after 4, 12 and 17 months of
treatment. Laboratory investigations included urinalysis,
measurement of haemoglobin concentration, white cell count
and differential count, determination of blood glucose and
urea value, and serum creatinine, sodium potassium, chloride,
aspartate transaminase, alanine transaminase, alkaline phos-
phatase and uric acid levels.
Untoward effects were evaluated by asking patients at each
visit whether they had experienced any problems since their
last visit. Significance of difference between values was
evaluated using paired and unpaired [-tests. Statistical sig-
nificance was established at the 0,05 confidence level. Values
are expressed as mean ± standard error of the mean.
Results
During diltiazem treatment blood pressures decreased signifi-
cantly (P < 0,0001). Representative values at 9 months were:
systolic blood pressure fell from a mean of 152,5 ± 11,0
mmHg to a mean of 133,3 ± 15,2 mmHg in the supine
position and from 144,3 ± 12,1 mmHg to 128,1 ± 13,3 mmHg
(P <" 0,0001) in the upright position. Diastolic blood pressure
fell from a mean of 105 ± 6,1 mmHg to a mean of 84,7 ± 10,7
mmHg in the supine position and from a mean of 106,5 ± 4,8
mmHg to a mean of 89,2 ± 11,0 mmHg in the standing
position (Fig. I). These reductions were maintained for both
systolic and diastolic blood pressures in both supine and
standing positions for the duration of the 17 months of
observation (Fig. I).
In 4 patients the supine diastolic blood pressure could nor
be reduced to < 90 mmHg or by at least 10 mmHg for
patients with a baseline value of> lOO mmHg. In 3 of these
patients the SR diltiazem had to be increased to 180 mg twice
daily and in the fourth patient the blood pressure remained
~controlled in spite of the double dose and a ~-blocker was
added in order to achieve adequate control.
o side-effects were noted in any of the patients. No
significant changes in the mean values of the laboratory data
were noted.
Discussion
In practically all cases of essential hypertension, the increase
in blood pressure is due to an elevation of vascular resistance.
Vascular resistance is determined by the smooth-muscle tension
in the arterioles.2 The predominant action of calcium antago-
nists is the dose-dependent inhibition of the slow inward
calcium current in the vascular smooth-muscle cells3 and, as
such, they may be potentially useful in the treatment of
hypertension. In fact, these agents are now well established as
potent antihypertensive agents. The clinical efficacy of the
available calcium-ehannel blockers is, however, hampered by
their relatively short half-lives.
In consonance with other studies,4-7 the present study
showed that long-acting SR diltiazem was efficacious and safe.
In the majority of patients (23 out of 27) with mild-to-
moderate hypertension, adequate blood pressure reduction
was obtained with SR diltiazem 90 mg administered twice
daily. No side-effects were noted during the 17 months'
duration of the study. The simplified administration regimen
should improve patient compliance in the long-term treatment
of hypertension.
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